Aims/hypothesis Carnitine palmitoyltransferase-1 (CPT1)c is a novel isoform in the CPT1 family and is found specifically in the brain. Cpt1c knockout (KO) mice are more susceptible to high-fat diet (HFD)-induced obesity. However, the underlying mechanism of this phenotype and the question of whether CPT1c is involved in the pathogenesis of diet-induced insulin resistance are unclear. Methods To assess the potential role of CPT1c in the regulation of whole-body glucose homeostasis, we generated Cpt1c KO mice and challenged them with HFD or standard chow. Glucose homeostasis of each group was assessed weekly.
Introduction
The prevalence of obesity and associated insulin resistance has increased dramatically, prompting an extensive search for underlying mechanisms [1, 2] . Recent evidence has demonstrated that nutrient metabolism in the central nervous system (CNS), specifically the hypothalamus, plays a key role in regulating peripheral energy homeostasis [3] [4] [5] [6] [7] [8] . Indeed, lipid metabolism in the hypothalamus is believed to be one of the most critical steps in central integration and modulation of whole-body energy balance [4, [9] [10] [11] [12] [13] . Carnitine palmitoyltransferase-1 (CPT1) is the rate-limiting enzyme in fatty acid β-oxidation, and works by regulating entry of long-chain fatty acids into mitochondria [14] . Inhibition of hypothalamic CPT1 activity by molecular and pharmacological approaches significantly decreases endogenous glucose production [15, 16] . Conversely, reducing the level of malonyl-CoA, the allosteric inhibitor of CPT1, by overproduction of malonyl-CoA decarboxylase increases endogenous glucose production [17] .
There are three isoforms of CPT1: the liver isoform CPT1a, muscle isoform CPT1b and a brain-specific isoform recently identified in mouse and humans, CPT1c [14, 18] . CPT1c shares a high primary sequence homology with CPT1a, which is also produced in the CNS [15, 18, 19] and displays comparable binding affinity for malonyl-CoA [18, 20] . However, CPT1c has some distinct characteristics, such as being primarily localised in endoplasmic reticulum rather than mitochondria; moreover, the specific palmitoyl-transfer activity of CPT1c was 20 to 300 times lower than that of CPT1a [21] . As opposed to the lethality of complete Cpt1a and Cpt1b deficiency [22, 23] , Cpt1c knockout (KO) mice survive and are more susceptible to high-fat diet (HFD)-induced obesity [20, 24] . Excess levels of CPT1c in hypothalamus protects mice on HFD from excessive weight gain [25] . However, it is unclear whether CPT1c is involved in the pathogenesis of diet-induced insulin resistance.
In this study, we generated Cpt1c KO mice and investigated the role of CPT1c as a mediator of wholebody glucose homeostasis and the mechanisms via which CPT1c-dependent alterations occur. We confirmed the increased susceptibility of these mice to HFD-induced obesity and insulin resistance. We then investigated the mechanisms underlying this observation by analysing hepatic gluconeogenesis and skeletal muscle glucose uptake. We also examined changes in fatty acid oxidation and oxidative gene expression in peripheral tissue, as well as changes in Cpt1 expression and activity in the CNS of these KO mice.
Methods
Targeting Cpt1c allele A mouse clone was isolated by screening a library made with genomic DNA from a 129Sv mouse strain with a cDNA encoding murine Cpt1c as a probe. A 6.7 kb fragment of the mouse Cpt1c genome containing coding exons 1 to 6 was used to construct a targeting vector and a 1.3 kb fragment containing the sequence of exon 3 was deleted. The targeting vector also included a positive neomycin (Neo)-Pgk selection cassette and a negative Pgk-diphtheria toxin (DT) selection cassette. We transfected 129Sv embryonic stem cells with a linearised targeting vector by electroporation. After selection, clones with a targeted allele were identified by PCR analysis. Embryonic stem cells with the targeted allele were injected into blastocysts of C57BL/6J mice and chimeric males were mated with females of the same strain to obtain heterozygous mutant mice, which were then intercrossed to obtain homozygous and wild-type (WT) mice. The frequency of homozygous, WT and heterozygous pups in the offspring of heterozygous parents reflected a Mendelian distribution. Male mice were chosen for further analysis as detailed below. All experiments with animals were approved by the Animal Care and Use Committee of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences.
Standard chow and HFD feeding Male mice (7 weeks old) were housed in metabolism cages and maintained on a 12 h light-dark cycle at 23°C and fed standard chow (15.9 kJ/g, 10% of energy as fat, 20% of energy as protein, 70% of energy as carbohydrate; GB14924; Guangdong Medical Laboratory Animal Center, Guangzhou, China) or HFD (21.9 kJ/g, 60% of energy as fat, 20% of energy as protein, 20% of energy as carbohydrate; D12492; Research Diet, New Brunswick, NJ, USA) according to the experimental design. Food intake was measured daily and body weight was measured weekly during the experimental phase in all experiments. For body temperature measurement, mice were held loosely in a small cloth bag and the core body temperature was measured using a digital thermometer with a resolution of 0.1°C (MT-132; Mother Tool, Ueda, Japan). The thermometer probe was inserted 25 mm into the rectum.
Plasma constituents analyses Blood samples were taken from cut tail tips of conscious overnight fasted mice. Plasma was collected for measurement of constituents. Plasma triacylglycerol and cholesterol were measured using commercial kits (Triacylglycerol Kit and Cholesterol Kit; Jiancheng, Nanjing, China). Plasma leptin was measured by a kit (Mouse/Rat leptin ELISA kit; Biovendor, Modrice, the Czech Republic).
Metabolic analyses; glucose and insulin tolerance tests A bolus of glucose (2 g/kg of body weight) or insulin (0.5 U/kg of body weight) was administered by intraperitoneal injection to mice previously fasted for 6 h (from 09:00 to 15:00 hours). Blood glucose was monitored from the tail vein blood using a glucometer (ACCU-CHEK Advantage; Roche Diagnostics China, Shanghai, China) before or 15, 30, 60 and 120 min after glucose or insulin administration. Insulin level was measured by a mouse insulin ELISA kit (Mercodia, Uppsala, Sweden). The pyruvate tolerance test was performed as described [26, 27] . For plasma NEFA analysis, food was removed from each group at 08:00 hours and plasma NEFA concentrations at 0, 1, 2, 6 and 12 h after food removal were monitored from tail vein blood using a commercial kit (NEFA Kit; Jiancheng).
Metabolic analysis in tissues
The method for tissue triacylglycerol extraction and determination was as described previously [28, 29] . Glycogen analysis was performed using a commercial kit (Glycogen Kit; Jiancheng). Glucose uptake analysis of skeletal soleus muscle in vivo or in vitro was determined as described [30, 31] . Measurement of fatty acid oxidation of liver and skeletal soleus muscle in vitro was performed as described [32] with slight modification. Details on tissue analysis are given in the Electronic supplementary material (ESM).
RNA interference strategy to knock down CPT1c in neuroblastoma cells We used a vector-based RNA interference (RNAi) approach to produce intracellularly a doublestranded short hairpin RNA (shRNA) from a DNA template under the control of the U6.2 promoter. Annealed oligonucleotides were cloned into the BamHI-XhoI sites of the pRNAT-U6.2/Lenti vector (GenScript, Piscataway, NJ, USA) and were designed to target the coding sequence of Cpt1c from site 21 to 50. The sequence of the oligonucleotides was: 5′-GGATCCCGTCGGAACTCAGTGAAGAC A G C A A G C T C G AT T G ATAT C C G T C G A G C T T GCTGTCTTCACTGAGTTCCGATTTTTTCCAACTC GAG -3′. Stable cells with Cpt1c shRNA expression were used for further analysis (for details see ESM). Palmitate (Sigma, St Louis, MO, USA) was dissolved in 95% ethanol (vol./vol.) at 60°C and then mixed with pre-warmed BSA (molar ratio: 4:1) to yield a stock concentration of 10 mmol/l. Palmitate was added to the medium and cells were collected for analysis 10 h later.
Measurement of CPT1 activity Mitochondria of muscle, liver, hypothalamus and neuroblastoma (N2a) cells were prepared as described previously [16, 20, 33] , protein concentrations determined using the Bradford assay and CPT1 activity assayed as described [34, 35] with slight modification. The details are given in the ESM.
Gene expression analysis Total RNA was isolated from cells or tissues of mice fasted for 6 h using Trizol reagent (Invitrogen China, Guangzhou, China) and isolated total RNA was reverse-transcribed with Superscript III reverse transcriptase (Invitrogen). For real-time PCR analysis, cDNA samples were used in quantitative PCR reaction in the presence of fluorescent dye Cybergreen (Bio-Rad, Benicia, CA, USA). The following PCR conditions were applied: 5 min, 95°C; 40×(10 s, 95°C; 20 s, 60°C; 1 s, 70°C
). After each elongation step, the reaction was quantified in a reading step and the product quality tested by melting curve analysis. Relative abundance of mRNA was calculated after normalisation to Gapdh mRNA. Sequences for the primers used in this study are shown in ESM Table 1 .
Western blot analysis CPT1c immunoblotting in tissue or cells was done using polyclonal CPT1c antibody, which was produced in rabbits against the peptide CKTVDP NTPTSSTNL coupled with keyhole limpet haemocyanin. The antibody was tested against epitope-tagged mouse CPT1c and mouse CPT1a constructs and shown to be specific to CPT1c.
Statistical analysis Data are expressed as mean±SEM. All comparisons were analysed by unpaired, two-tailed Student's t test. Pearson correlation coefficient was used to establish the association between plasma NEFA concentration and both increased CPT1 activity and Cpt1 mRNA fold change in hypothalamus. A p value of p<0.05 was considered significant. 
Results
Generation of Cpt1c KO mice To study the physiological role of CPT1c in vivo, we produced a disruption of Cpt1c using a targeting vector designed to replace exon 3 with Neo-Pgk gene cassette (Fig. 1a) . The genotype of these offspring was identified by tail genome PCR (ESM Fig. 1 ).
Western blot analysis in whole brain showed that the Cpt1c KO mice were completely deficient in CPT1c protein (Fig. 1b) . These mice were then used for metabolic analyses. Wolfgang et al. also recently generated Cpt1c KO mice using a different genetic strategy [20] . Importantly, our Cpt1c KO mice display a similar basic phenotype to that of previously described mice, thus confirming the role of CPT1c in regulating peripheral glucose homeostasis. In this study we performed a detailed mechanistic analysis of this phenomenon. Some important differences between our approach and that of Wolfgang et al. are outlined in Table 1 .
Cpt1c KO mice are more susceptible to HFD-induced insulin resistance To determine whether CPT1c was involved in the onset of diet-induced insulin resistance, we fed the Cpt1c KO and WT mice standard chow or HFD and assessed glucose homeostasis in each group weekly. After 8 weeks of feeding, the body fat mass of HFD Cpt1c KO and WT mice was markedly increased compared with standard chow controls, while there was no significant difference between Cpt1c KO and WT mice in HFD and standard chow groups (ESM Table 2 ). No differences in fasting glucose and insulin levels were observed between the two types of mice under standard chow condition (ESM Fig. 2a, b) . However, Cpt1c KO mice showed significantly higher fasting glucose and insulin levels than WT mice on HFD (ESM Fig. 2a, b) . To further assess insulin sensitivity of each group, we performed a glucose tolerance test (GTT) and insulin tolerance test (ITT). As illustrated in Fig. 2a , b, HFD significantly decreased the insulin sensitivity of each mouse type. Specifically, compared with WT HFD mice, Cpt1c KO mice on HFD developed more severe insulin resistance. The AUC of GTTs and ITTs further supported the significant difference between KO and WT mice on HFD (Fig. 2c) . We also showed that the glucose intolerance of WT mice after 24 weeks of HFD feeding was worsened to the same extent as that of KO mice after 8 weeks of HFD feeding, despite a significant increase in body weight gain and body fat (Fig. 2d-f) . Notably, in both types of mice on HFD circulating NEFA increased significantly (Fig. 2g ).
Cpt1c KO mice on HFD exhibited increased gluconeogenesis To determine gluconeogenesis in vivo, we measured the blood glucose levels of mice following intraperitoneal injection of pyruvate, an important substrate of gluconeogenesis. The results showed that HFD feeding enhanced the rate of pyruvate conversion into glucose and that Cpt1c KO mice on HFD exhibited a higher converting rate than WT mice under the same feeding regimen (Fig. 3a) . mRNA levels of hepatic glucoregulatory genes G6pc and Pck1 were significantly increased in WT mice on HFD and to an even greater degree in Cpt1c KO mice (Fig. 3b) . Liver glycogen content of these two types of mice on HFD was similar (ESM Fig. 2c ), suggesting that glycogenolysis is not an important factor contributing to the increased endogenous glucose levels of Cpt1c KO mice on HFD. However, liver triacylglycerol content was increased in KO mice fed HFD (Fig. 3c) , which was associated with significant decreased total CPT1 activity ( Fig. 3d ) and fatty acid oxidation (Fig. 3e) . Consistent with this, the expression of genes promoting fatty acid oxidation and energy metabolism, including Cpt1a, Acadm, Pdk4, Cox2, Cox3 and Cs, was markedly decreased in Cpt1c KO mice on HFD compared with WT mice (Fig. 3f) .
Cpt1c KO mice on HFD showed decreased glucose uptake in skeletal muscle To assess whether alterations in peripheral glucose uptake are also responsible for the impaired glucose tolerance in Cpt1c KO mice on HFD, we analysed glucose uptake in vivo. After 8 weeks of HFD feeding, glucose uptake in skeletal muscle was considerably decreased in Cpt1c KO mice on HFD compared with WT controls (Fig. 4a) . Glucose uptake in white adipose and brown adipose tissue of Cpt1c KO and WT mice was significantly decreased compared with standard chow controls, while there was no significant difference between Cpt1c KO HFD mice and WT controls (data not shown). The isolated skeletal muscle was used to further analyse the glucose uptake defect in muscle of Cpt1c KO mice on HFD. The results showed that under insulin stimulation, the glucose uptake capacity was significantly decreased in isolated muscle of Cpt1c KO mice on HFD compared with that of WT mice, while there was no significant difference in non-insulin-stimulated glucose uptake among each of these groups (Fig. 4b) . To eliminate the effect of glucose 6-phosphatase on the accumulation of 2-deoxy[ 3 H]glucose-6-phosphate, we examined the G6pc mRNA level in skeletal muscle of each group of mice. In contrast to liver, the mRNA levels of G6pc in skeletal muscle of Cpt1c KO HFD mice and WT controls were similar (ESM Fig. 3a) . A significantly reduced glycogen content and elevated triacylglycerol content were observed in skeletal muscle of Cpt1c KO mice on HFD (Fig. 4c, d) , with no significant difference detected between Cpt1c KO and WT mice on standard chow. Also, these alterations were correlated with decreases in CPT1 activity and fatty acid oxidation in muscle (Fig. 4e,  f) . These results are consistent with the downregulation of oxidative genes expression, including Cpt1b, Acadm, Pdk4, Cox2, Cox3, Cs and Ppargc1a, seen in Cpt1c KO mice on HFD compared with the WT mice (Fig. 4g) .
Hypothalamic CPT1 activity was increased in Cpt1c KO mice on HFD All three members of the CPT1 family are expressed in the hypothalamus. Therefore, we sought to examine whether Cpt1c deletion alters Cpt1a or Cpt1b expression and activity in the hypothalamus. We found a substantial increase in the hypothalamic mRNA levels of Cpt1a and Cpt1b in Cpt1c KO mice on HFD compared with those in WT mice; there was no difference between these two types of mice on standard chow (Fig. 5a ). Cpt1c expression in the hypothalamus of WT mice was not changed by 8 weeks of HFD feeding (ESM Fig. 3b, c) . We did not observe any marked difference of Cpt1a and Cpt1b transcript levels in other CPT1c-rich regions between both Cpt1c KO and WT mice on HFD or those on standard chow (data not shown). Consistent with this, a considerably increased hypothalamic CPT1 activity in Cpt1c KO mice on HFD was observed compared with WT mice (Fig. 5b) . CPT1 activity in hippocampus and cortex of Cpt1c KO and WT mice on HFD or standard chow was similar (data not shown).
NEFA induced Cpt1a and Cpt1b expression in Cpt1c knockdown neuroblastoma To further investigate the underlying mechanism of the hypothalamus-specific compensatory effect, we selected the N2a cell as a tool. Real-time PCR analyses showed that all the Cpt1 members were expressed in N2a cells and that the Cpt1 expression profile of N2a cells was very similar to that of hypothalamus (Fig. 5c) , indicating that N2a cell is a suitable in vitro model to examine the effect of Cpt1c deficiency on Cpt1a and Cpt1b expression in hypothalamus. To this end, we (Fig. 5d, e) . We postulated that the increased plasma NEFA concentrations of the HFD feeding group could induce Cpt1 expression in hypothalamus of Cpt1c-deficient mice. No significant difference between Cpt1a and Cpt1b was observed in Cpt1c shRNAi cells and control treatment when these cells were maintained in palmitate-free or lower palmitate medium (Fig. 5f, g ). However, when the palmitate concentration in medium was increased to 0.3 mmol/l, Cpt1a and Cpt1b expression in Cpt1c shRNAi cells was increased significantly compared with control ( Fig. 5f, g ), while palmitate treatment did not change Cpt1c expression significantly in control cells (ESM Fig. 3d, e) . Analysis of corresponding total CPT1 activity under these conditions confirmed the ability of palmitate to significantly induce CPT1 activity at 0.3 mmol/l in cells lacking Cpt1c (Fig.  5h ). This point is reinforced by the clear positive correlation between circulating NEFA and hypothalamic Cpt1 expression (Fig. 5i ) and activity (ESM Fig. 4 ).
Discussion
Previous studies have established that lipid metabolism in the CNS is an important mechanism regulating maintenance of systemic glucose homeostasis. CPT1, the rate-limiting enzyme in fatty acid oxidation, along with its allosteric inhibitor malonyl-CoA and its substrate long-chain fatty acid-CoA, constitutes an intricate sensing feedback loop, which can regulate metabolic processes in response to the changing nutrient status of the body [3, [15] [16] [17] 32] .
However, it has been demonstrated that lipid metabolism in CNS and in peripheral tissues has opposing physiological effects despite sharing similar biochemical/molecular mechanisms [16, 17, [36] [37] [38] . Specifically, inhibition of CPT1 in the hypothalamus suppresses glucose production in liver [15, 16] , while inhibition of liver CPT1 with etomoxir induces liver insulin resistance [37] . The central administration of C75, a potent inhibitor of fatty acid synthase, increases malonyl-CoA concentration in the hypothalamus, while activating fatty acid oxidation in skeletal muscle [32, 36] . CPT1c is a novel brain-specific CPT1 isoform. Previous reports have shown that CPT1c had no enzyme activity in yeast or HEK293T cells with palmitoyl-CoA or other acylCoA molecules as substrate, and that CPT1c is localised in mitochondria [18, 20, 25] . However, a recent study demonstrated CPT1c localisation in the endoplasmic reticulum of the neuron and also that CPT1c has palmitoylcarnitine-specific transferase activity, albeit much lower than other CPT1 isoforms [21] . Studies by Wolfgang et al. [20] , and now ourselves using independently generated Cpt1c KO mice, have demonstrated that these mice display higher susceptibility to HFD-induced obesity and insulin resistance. Our current study was designed to gain insight into the mechanisms via which Cpt1c deficiency causes greater susceptibility to HFD-induced insulin resistance and is clearly distinct yet complementary to the previous study of Cpt1c deletion as outlined in Table 1 . Although the genetic background of mice in our study is different from that of the previous study [20] , a similar susceptibility of Cpt1c KO mice to HFD-induced obesity was also observed in our study (ESM Fig. 5a-c) , indicating that genetic background has no major effect on the physiological role of Cpt1c. In our study, after 8 weeks of feeding, the Cpt1c KO mice on HFD exhibited an apparently more severe insulin resistance than WT control mice, even before body fat mass or plasma NEFA diverged significantly. The glucose intolerance of HFD Cpt1c KO mice at 8 weeks of HFD feeding was similar to that of WT mice at 24 weeks of HFD feeding, despite a significant decrease in bodyweight gain and body fat. These data imply that Cpt1c KO mice were more susceptible than WT controls to impaired insulin resistance and that this was independent of obesity. Additionally, our results indicate that the impaired glucose tolerance in Cpt1c KO mice on HFD could be, at least in part, explained by increased hepatic gluconeogenesis and decreased muscle glucose uptake. The elevated gluconeogenesis was illustrated by the enhanced converting rate of pyruvate to glucose and by elevated expression of G6pc and Pck1. The decreased glucose uptake in skeletal muscle also showed the contribution of skeletal muscle to the phenotype of Cpt1c KO mice on HFD. In this regard, the decreased glycogen content in skeletal muscle of Cpt1c KO mice on HFD is likely to be due to decreased insulin-stimulated glycogen synthase activity and glycogen synthesis [39, 40] . In this study, we also report that Cpt1c KO mice fed on HFD exhibited elevated levels of the other two functional CPT1 isoforms, CPT1a and CPT1b, specifically in hypothalamus. This was not observed in Cpt1c KO mice on standard chow or in WT mice on HFD and standard chow. The increased plasma NEFA concentration of the HFD feeding group was identified as the possible causative factor of the hypothalamic Cpt1 compensatory effect. Hypothalamus is the most important brain region for sensing circulating nutritional NEFA levels and in turn modulates global glucose homeostasis [16, 41] ; in fact, in our current study the same compensatory effects were not found in other brain regions. Moreover, various brain regions exhibit different lipid metabolism profiles under same treatment conditions [15, 16] . As a critical regulatory factor of lipid metabolism, the Cpt1 expression profile is quite different in various brain regions and these differences have been shown to be correlated with different metabolic responses to circulating NEFA even between two brain regions that are very close together [15, 16] . Hence, we selected the N2a cell, which exhibits similar Cpt1 expression profile to hypothalamus, to investigate the underlying mechanism of this hypothalamic compensatory effect. Indeed, our demonstration that NEFA can induce Cpt1 expression in this cell line and the correlation of circulating NEFA with hypothalamic Cpt1 expression and activity confirm this potential mechanism.
We also detected decreased fatty oxidation and oxidative genes expression in liver and skeletal muscle and so it appears that the opposing responses of oxidative enzymatic activity in central and peripheral systems ultimately contribute to impaired glucose tolerance [17, 37, 42] . This could be the primary defect, from which the metabolic disturbance of Cpt1c KO mice originates. Therefore, the compensatory effect of functional Cpt1 in hypothalamus and the adverse effect of decreased peripheral energy metabolism in Cpt1c KO mice provide a possible, initial mechanistic explanation of the phenotype of Cpt1c KO mice on HFD while confirming an important function of this brain-specific CPT1 isoform in whole-body energy regulation. Although the CPT1 activity of CPT1c is very low, the capacity of CPT1c to bind malonyl-CoA is similar to that of CPT1a [20] . Thus, we hypothesise that hypothalamic CPT1c binds malonyl-CoA and thus, through this binding, regulates the availability of intracellular malonylCoA. Deficiency of CPT1c makes more malonyl-CoA available, especially under HFD conditions; as a result, the subsequently decreased CPT1 activity indicates that fatty acid oxidation was blunted, with substrate accumulation possibly inducing functional CPT1 production in hypothalamus via a compensatory feedback mechanism. Clearly, additional rigorous experimentation is needed to validate this hypothesis. Similarly, further dedicated studies will be necessary to define whether the peripheral metabolic changes are the results of CPT1c deficiency or the secondary consequence of increased functional Cpt1 expression in CNS.
In summary, we have shown that under HFD feeding conditions, Cpt1c KO mice were more susceptible to HFDinduced insulin resistance. This manifested as defects in gluconeogenesis and muscle glucose uptake and could be partially attributed to defective energy metabolism in these tissues. Consistent with the peripheral hyperglycaemia in these mice, we further observed a compensatory elevation of two other CPT1 isoforms in the hypothalamus of Cpt1c KO mice on HFD and identified increased plasma NEFA concentration as the possible causative event for this compensation. These results indicate a possible function of CPT1c in regulating energy homeostasis during times of energy surplus.
